The Prostate Cancer Prevention Trial (PCPT) compared the ability of the 5 ␣ -reductase inhibitor fi nasteride (5 mg/day) versus placebo to reduce the risk of prostate cancer. Prostate cancers were detected during the study by "for-cause" biopsy following an abnormal digital rectal examination (DRE) and/or elevated serum prostate-specifi c antigen (PSA) level or in end-of-study biopsies that were performed regardless of DRE/PSA status.
prostate cancers identified during the 7-year period of the trial, including those in the end-of-study biopsies, in the finasteride group ( 1 ) . However, the proportion and number of high-grade tumors (defined as Gleason score 7 -10) were higher in the finasteride group than in the placebo group: 280 of 757 (37.0%) of the graded tumors (and 6.4% of evaluated men) in the finasteride group versus 237 of 1068 (22.2%) of the graded tumors (and 5.1% of evaluated men) in the placebo group. This finding raised concerns over the safety of finasteride for prostate cancer prevention ( 2 , 3 ) . It has been proposed that finasteride increases the risk of high-grade cancer through changes in intraprostatic androgen and/or estrogen signaling ( 4 -7 ) . The increased risk of high-grade disease with finasteride in the PCPT, however, was noted in the first year, and the relative risk (RR) did not increase over time, raising the suspicion that the increase may have been due to causes other than induced aggressive disease ( 8 , 9 ) .
Finasteride alters the levels of intraprostatic androgens, which may have morphologic effects on prostatic carcinomas and cause lower grade tumors to appear higher grade ( 10 -13 ) . Finasteride reduced prostate volume by an average of 24% in the PCPT ( P <.001) and has recently been found to increase the sensitivity of both DRE and PSA for cancer detection, which jointly could have improved the detection of high-grade tumors in the treatment arm ( 14 -17 ) .
This study addresses these potential volume and pathologic biases by using a detailed pathologic analysis of biopsies with high-grade cancer and prostatectomies from the PCPT. Specifi cally, we report on the results from a panel of pathology experts who blindly examined high-grade biopsies to evaluate whether there was evidence of a hormonal artifact in the fi nasteride group compared with placebo. We compared pathologic stage and margin status in prostatectomies and measures of disease extent in high-grade biopsies between treatment groups to see whether there was evidence that high-grade cancers from the fi nasteride group had indications of greater disease extent. In the subset of men for whom we had both biopsy and prostatectomy specimens, we compared Gleason grading patterns to determine whether needle biopsy of the smaller volume prostates in the fi nasteride group led to improved detection of high-grade cancer foci compared with the placebo group, using grade at prostatectomy as the gold standard for the presence of high-grade disease.
Subjects and Methods

Cancer Diagnosis in the Prostate Cancer Prevention Trial
A total of 18 882 men were randomly assigned to either finasteride (5 mg/day orally, n = 9423) or placebo (n = 9459). All patients provided written informed consent, and the study was approved by each study site's Internal Review Board. Participants had annual DRE and PSA measurements, and prostate biopsy was recommended if either test was abnormal. Because finasteride lowers serum PSA, annual PSA values in the finasteride group were adjusted upward, by a factor of 2.0 initially that then increased to 2.3 after year 4, to keep pace with biopsies in the placebo group ( 1 ). To minimize bias from this PSA adjustment, the protocol specified an end-of-study biopsy at the end of 7 years, with a minimum of six cores, for all subjects without a prior diagnosis of prostate cancer. Prostate volume at biopsy was measured by transrectal ultrasound. Treatment for prostate cancer diagnosed in the PCPT was not specified, and information about treatment received was not collected systematically.
A histologic diagnosis of prostate cancer on needle biopsy was established by the pathologist (G. J. Miller, MD, PhD, until May 2001, M. S. Lucia thereafter) at the PCPT Core Pathology Laboratory (CPL) and by the pathologist at the participant's study site. Disagreements between these two pathologists were resolved by a consensus diagnosis involving an arbiter pathologist. Tumor grading was provided by the CPL pathologist (M. S. Lucia), who was blinded to the participant's study group. The CPL pathologist reviewed 94.3% of all PCPT cancer biopsies. The fi nal biopsy Gleason score included the biopsy core with the highest grade tumor ( 18 , 19 ) .
CONTEXT AND CAVEATS
Prior knowledge
Results from the Prostate Cancer Prevention Trial (PCPT) indicated a higher incidence of high-grade prostate cancer among men who were treated with finasteride than men who were treated with placebo.
Study design
Disease extent in prostate biopsies with high-grade tumors (Gleason score 7 -10), prostate gland volume, and tumor grade and extent in radical prostatectomy samples were compared among men who were treated with finasteride and men treated with placebo in the PCPT.
Contributions
Men who were treated with finasteride had reduced tumor extent in prostate biopsies and lower prostate gland volumes than men who were treated with placebo. The increase in high-grade disease observed at initial diagnostic needle biopsy in the finasteride group compared with the placebo group was less apparent at prostatectomy. In the finasteride group, needle biopsy identified a larger proportion of the men found to have high-grade disease at prostatectomy. Stage at prostactectomy and the proportion of men with prostate cancer that was upgraded from low grade to high grade at prostatectomy were similar in the two groups.
Implications
The increase in high-grade prostate cancer incidence with finasteride observed in the PCPT may have been due in part to effects of finasteride on prostate gland volume and reduced low-grade cancer rather than to effects on tumor morphology or biology.
Limitations
Not all men who had biopsies had prostatectomy, and unknown differences among the men who did and did not might have affected the findings in the two groups. This was a multicenter study, and different centers used different methods to prepare prostatectomy samples for analysis, which may have led to variations in the detection of high-grade disease. In addition, long-term outcomes, such as death from prostate cancer or overall survival, were not followed in this study. consensus, developed a set of pathologic criteria for potentially discriminating the degenerative changes caused by finasteride from the histologic appearance of tumors in placebo-treated subjects. A training set of 29 cancers with Gleason score 8 -10 from the placebo (n = 10) and finasteride (n = 19) groups were examined in an unblinded fashion to identify individual features that suggested a degenerative effect of finasteride on the cancer that could potentially interfere with proper grading. The sample size was chosen because it was felt that it would provide a diverse enough sample to characterize any patterns of change without unblinding too many samples. Based on this preliminary review and histologic changes known to occur with hormone ablation ( 10 , 11 ) , nine potentially discriminating criteria were selected: nuclear size (large = larger than normal epithelial nucleus, small = equal or smaller than normal epithelial nucleus), nuclear smudge (loss of chromatinic detail), nucleolar prominence, cytoplasmic vacuolization, stromal fibrosis, intratumoral inflammation, empty clefts, apoptosis, and mitotic figures. The panel then conducted a blinded review of biopsy cores from the remaining tumors with Gleason score 8 -10 (n = 90, finasteride; n = 52, placebo) and quantified the number (per ×400 field) of apoptotic bodies and mitoses and the extent (percent area) of tumor (0 = 0%, 1 = ≤ 5%, 2 = 6% -25%, 3 = 26% -50%, 4 = 51% -75%, 5 = >75%) that showed the other degenerative features.
Pathologic Features at Prostatectomy and Grading Comparison Between Biopsy and Prostatectomy
Pathologic materials were requested for all patients who were known to have undergone radical prostatectomy, regardless of grade, and every prostatectomy specimen received by the CPL (n = 528; 222 finasteride, 306 placebo) was analyzed by one pathologist (M. S. Lucia), who was blinded to treatment assignment. All prostatectomy specimens were processed in accordance with published guidelines ( 20 ) . Tumor Gleason score ( 18 ) in the prostatectomy specimens was based on the predominant and secondary tumor pattern. Tumors from men treated with hormonal ablation therapy before prostatectomy (n = 28) were not graded because of the known effects of the therapy on grading ( 10 , 11 , 13 ) . Tumors were staged using 1997 American Joint Committee on Cancer guidelines ( 21 ) and were considered margin positive if tumor was present at the inked surface of the specimen. Biopsy and prostatectomy specimens were available for comparison from 206 men in the finasteride group and 283 men in the placebo group.
Biopsy Analysis of Disease Extent Parameters
Complete biopsy materials were available for 282 of the 288 men in the finasteride group with Gleason score 7 or greater and 244 of the 252 men in the placebo group with Gleason score 7 or greater. The CPL pathologist recorded features associated with tumor extent, including total number of biopsy cores, number and percentage of cores positive for cancer, greatest linear extent of cancer (mm) for each core (measured by an optical reticule), aggregate linear extent (mm) of cancer within all cores, bilateral involvement (if known), and perineural invasion ( 19 , 22 -25 ) .
Statistical Methods
Comparisons between the finasteride and placebo groups used the following tests: the chi-square and Fisher exact tests (as appropriate) for comparing the pathologic features of prostatic carcinomas and patient characteristics at prostatectomy and the Mann -Whitney test and chi-square tests for comparing the biopsy characteristics of Gleason score 7 -10 tumors. For the hormonal artifact analysis, results were analyzed to determine whether the criteria could identify a "finasteride-treated" tumor within this group of tumors. Logistic regression models were formed to evaluate the discriminative capability of the criteria with the concordance index, and the estimates were corrected using bootstrapping methods to reduce the optimistic bias in the concordance index. The logistic regression models considered each criterion as either a binary variable split at the median value for that criterion or as a continous variable using restricted cubic splines.
The extended Mantel -Haenszel correlation statistic was used to evaluate the pattern of up-and downgrading of Gleason scores from biopsy to prostatectomy. A general chi-square test was used to test for differences in sensitivity of the needle biopsy between treatment groups. In the dichotomous analysis, high-grade tumors were defi ned as those with Gleason score 7 or greater and lowgrade tumors were defi ned as those with Gleason score 6 or less.
All statistical tests were two-sided. P values less than .05 were considered statistically signifi cant. Statistical analyses were done using SAS, version 9.0 (SAS Institute, Inc, Cary, NC) and S-Plus 2000 (Insightful Corp, Seatlle, WA).
Results
A total of 1901 participants (n = 778 finasteride; n = 1123 placebo) were diagnosed with prostate cancer on biopsy in the PCPT as of June 23, 2003 , when the treatment results were made public ( Table  1 ). This includes 76 tumors (n = 21 finasteride; n = 55 placebo) that were graded after the dataset was frozen for the original report (1) and reflects diagnoses of prostate cancer within 7 years (+90 days) of the date that the participant was randomly assigned to treatment. In the finasteride group, 288 cancers (37.4% of graded tumors) were Gleason score 7 or greater, whereas there were 252 such cancers (22.7% of graded tumors) in the placebo group. [27. 1%] placebo), although this difference did not achieve statistical significance ( P = .07).
Biopsies of tumors with Gleason score 8 -10 (n = 90, fi nasteride; n = 52, placebo) were examined for degenerative changes by the pathology review panel. Specimens from eight other patients (one fi nasteride and seven placebo) could not be obtained from their study sites. Degenerative changes that were considered suffi ciently severe to have potentially impacted accurate grading were found in 30 of 90 (33.3%) patients in the fi nasteride group and in 17 of 52 (32.7%) patients in the placebo group, which prompted examination of the nine specifi c morphologic features that were potentially capable of discriminating between fi nasteride-treated and untreated (placebo) tumors ( Table 2 ). In logistic regression models, none of the nine criteria could discriminate between treatment groups when considered as either a binary or a continuous variable. The ability of the overall model to discriminate between treatment groups when each criterion was included as a covariate had a bootstrap-corrected concordance index of 0.51, i.e., no better than that expected by chance. Thus, degenerative changes were present in equivalent percentages of tumors of both the fi nasteride and placebo arms, and no distinctive histopathologic features distinguished the tumors of either group.
The CPL examined 528 prostatectomy specimens of PCPT participants (n = 222 fi nasteride; n = 306 placebo) to determine tumor characteristics at prostatectomy for the two groups. As a group, participants with a known prostatectomy were younger, were more likely to be white, were more likely to have been diagnosed on a for-cause biopsy, and had higher PSA values than those without prostatectomy ( Table 3 ) . Despite the greater proportion of partici pants with biopsy Gleason scores of 7 or greater in the fi nasteride group relative to placebo, in the prostatectomy samples no statistically signifi cant differences in pathologic stage, nodal involvement, or margin status between the two groups were observed, either overall ( Table 4 ) or in prostatectomies following a for-cause diagnosis versus an end-of-study diagnosis (data not shown).
Although prostatectomy specimens were processed in accordance with published guidelines at all sites that submitted prostatectomies ( 20 ) , study sites varied in the quantity of prostatic tissue sampled, ranging from complete to representative sampling of quadrants. For this reason, accurate tumor volumes across study sites could not be obtained.
Tumor grade at biopsy and prostatectomy were compared for the 206 fi nasteride and 283 placebo-arm tumors in which cancer grades on both specimens were available ( Table 5 ) . Because participants were off study treatment by the time of prostatectomy, degenerative changes were not quantifi ed as was done for the Gleason 8 -10 biopsies ( Table 2 ). Among patients who had both biopsy and prostatectomy (excluding those participants who received hormone therapy before prostatectomy), the difference in the percentage of high-grade * Each criterion scored on a scale of 1 -5 (0 = 0%, 1 = <5%, 2 = 6% -25%, 3 = 26% -50%, 4 = 51% -75%, 5 = >75%) for each tumor, except for apoptotic bodies and mitotic figures, which are expressed as number per high-power field (10 fields counted). † P values (two-sided) for univariate analyses were calculated using using a Wald test. ‡ P values (two-sided) for multivariable analyses were calculated using a Wald test. ( Table 5 , test of change in upgrading/downgrading distribution between groups, P = .09). If one assumes that the Gleason score at prostatectomy is the true disease grade, i.e., the "gold standard," then the sensitivity of biopsy to detect high-grade disease can be compared for each treatment group. Among patients who underwent biopsy and prostatectomy, the Gleason score at biopsy identifi ed high-grade (Gleason score ≥ 7) disease that was present at prostatectomy more often in the fi nasteride group (62 of 89 [69.7%]) than in the placebo group (53 of 105 [50.5%]) ( P = .01). However, among men who had a Gleason score of 6 or less at biopsy, the rate of upgrading to Gleason score 7 or greater was similar between the treat- We hypothesized that if fi nasteride does induce high-grade disease, pathologic surrogates may indicate greater disease extent for those cancers in the treatment group than in the placebo group. Because prostatectomy data were available for only a subset of the tumors detected in the PCPT, pathologic features of tumor extent were compiled from all available biopsies of men diagnosed with Gleason score 7 -10 tumors ( Table 6 ). Complete biopsy materials were available for 282 of 288 and 244 of 252 Gleason score 7 -10 tumors in the fi nasteride and the placebo groups, respectively. Pathologic surrogates of disease extent were lower on average in the fi nasteride than in the placebo group. These included percentage of cores positive for cancer (34% fi nasteride versus 38% placebo, difference = 4.7%, 95% CI = 1.3% to 8.1%; P = .016), linear extent of tumor (greatest [4.4 mm fi nasteride versus 4.8 mm placebo, difference = 0.4 mm, 95% CI = − 0.21 to 0.93 mm; P = .19], aggregate [7.6 mm fi nasteride, 9.2 mm placebo, difference = 1.6 mm, 95% CI = − 0.04 to 3.2 mm; P = .13]), bilateral involvement (22.8% fi nasteride, 30.6% placebo, difference = 7.8%, 95% CI = 0.1% to 15.4%; P = .046), and perineural invasion (14.2% fi nasteride, 20.3% placebo, difference = 6.1%, 95% CI = − 0.5 to 12.7%; P = .07). Median prostate gland volume in men with a biopsy Gleason score 7 -10 tumor was 25.1 cm 3 (fi nasteride) versus 34.4 cm 3 (placebo) ( P <.001). The fi nasteride-associated reduction in prostate gland volume was fi rst detected at year 1 0  14  6  1  1  10  28  8  1  3  6  7  65  20  0  4  12  100  43  0  6  7  2  12  28  6  2  1  13  38  3  1  8 -10  0  3  14  14  7  0  3  5  7  1 * Three men on finasteride and three men on placebo who had a prostatectomy had a biopsy that was not graded. † Extended Mantel -Haenszel correlation statistic (increase, unchanged, decrease) between groups, P = .03. ‡ NG = not graded (because of anti-androgen therapy between biopsy and prostatectomy).
(18.7%), when the increased risk of high-grade disease was fi rst noted (data not shown).
Discussion
Three possibilities, not mutually exclusive, may explain the increased prevalence of high-grade prostate cancer among men in the finasteride group of the PCPT ( 1 ). The first is that finasteride induces growth of high-grade cancer despite the decrease in lowgrade cancer. This study provides no data to support or refute the possibility that finasteride may have induced high-grade cancer in some men. The second possible explanation is that finasteride, through its effects on PSA, DRE, and prostate volume, increased detection of existing high-grade cancer. As previously reported, * These numbers reflect every prostatectomy sample received by the Core Pathology Laboratory; biopsy high-grade tumors graded in prostatectomies numbered 79 in the finasteride group and 70 in the placebo group (detailed in Table 5 ). † P values were calculated by using two-sided chi-square test, except for N stage and seminal vesicle invasion, which used a two-sided Fisher exact test. ‡ Grade 2 -6 versus grade 7 -10. § Not graded because of anti-androgen therapy between biopsy and prostatectomy. finasteride does increase the sensitivity of PSA and DRE for detecting cancer, particularly high-grade disease ( 16 , 17 ) , and the results of this study suggest that finasteride decreases prostate volume. Furthermore, selective inhibition of low-grade cancer in men with cancers that contain both low-and high-grade components could have increased the relative proportion of high-to low-grade cancer, thereby favoring detection of the high-grade component by needle biopsy. The third potential explanation is that finasteride interferes with the histologic grading of cancer, causing lower-grade tumors to appear high grade. Histopathologic changes with androgen ablation therapy are known to affect tumor grading ( 10 , 11 , 13 ) but are less established with fi nasteride ( 10 , 12 ) . Three genitourinary pathologists reviewed biopsies of the majority of tumors diagnosed as for features indicative of a hormonal degenerative effect ( Table 2 ). This group of tumors was chosen because the majority of the excess high-grade tumors in the fi nasteride group were Gleason grade 8 -10. We postulated that if grade differences between the two treatment groups were due to morphologic changes induced by fi nasteride, those changes should be evident in the tumors at the time of diagnosis. The panel of pathologists instead found similar histologic features in the two groups and concluded that a grading bias due to the effect of fi nasteride on tumor morphology was of insuffi cient magnitude to have caused the difference in high-grade tumors between the study arms.
Pathologic examination of the PCPT prostatectomy specimens revealed that the difference in proportion of high-grade tumors between the fi nasteride and placebo groups was diminished compared with the difference seen at biopsy (ratio of 1.68 at biopsy versus 1.20 at prostatectomy for graded tumors), despite the greater likelihood of radical prostatectomy for high-grade disease in subjects receiving fi nasteride. Pathologic stage and node and margin status were not different between treatment groups. Comparison of tumor grade on prostatectomy and biopsy showed that, when high-grade disease was present at prostatectomy, it was more likely to have been detected at biopsy in the fi nasteride group (62 of 89 [69.7%]) than in the placebo group (53 of 105 [50.5%]) ( P = .01), indicating that fi nasteride increased the sensitivity of prostate biopsy for high-grade disease.
Differences in detection of high-grade cancer by biopsy between the two treatment groups are refl ective of the random nature of prostate biopsies and the resulting potential for sampling error. The detection and grading of cancer on biopsy is subject to two factors: the ratio of tumor volume to prostate volume ( 26 , 27 ) (which affect overall detection) and the relative proportions of Gleason patterns that exist within the tumor (which affect grading). The greater the relative volume of any high-grade component, the more likely it will be sampled (28 -33) . Gland volume in the fi nasteride group (25.1 cm 3 ) was 27% smaller than in the placebo group (34.4 cm 3 , P <.001). Reduced prostate gland volume with fi nasteride may have increased the tumor-to-prostate volume ratio and improved detection of both cancer overall and any highgrade component of cancer. This hypothesis is supported by fi ndings of other investigators, who reported a relationship between smaller gland size and improved sensitivity of prostate biopsy for high-grade disease ( 33 ) .
Finasteride may also have caused a relative increase in the highgrade component by one of two other possible mechanisms. One could be that fi nasteride potentiates the growth of high-grade cancer. However, pathologic measures of tumor extent on biopsy ( Table 6 ) do not lend support to this conclusion. A second possibility, which is supported by the primary results of the PCPT ( 1 ) and studies involving another 5 ␣ -reductase inhibitor, dutasteride ( 35 ) , is that fi nasteride reduces the volume contribution of low-grade tumor. Because many carcinomas are a mixture of low-and high-grade components, such a reduction would alter the ratio of the two components within a gland containing both components so that, when biopsy is performed, the high-grade component is more likely to be sampled.
If fi nasteride does alter the tumor-to-prostate volume ratio, particularly for high-grade disease, by decreasing prostate volume, it would result in the detection of smaller tumors that could be missed in the larger glands of the placebo group. Because accurate tumor volumes could not be obtained from the prostatectomies due to differences in sampling techniques between sites, we examined surrogate measures of tumor extent on needle biopsies. Review of all high-grade (Gleason score 7 -10) biopsies showed that the number and percentage of cores with cancer, greatest linear and aggregate tumor extent, percent bilateral cancer, and percent perineural invasion were either decreased or similar in fi nasteride versus placebo high-grade tumors. These biopsy features are also infl uenced by the ratio of tumor-to-prostate volume ( 22 -27 , 34 ) . Because fi nasteride reduced gland volume, one would expect the values of these biopsy features to be greater in the fi nasteride group if those tumors were of the same size or larger than tumors in the placebo group. Lower values for these features in fi nasteride high-grade tumors compared with those in the placebo group are consistent with detection of lower volume disease. Therefore, it is plausible that decreased prostate volume with fi nasteride led to improved detection of high-grade but lower-volume cancers. It also is possible that an upward shift in grade due to the selective effect of fi nasteride on reducing the volume contribution of low-grade tumor components contributed to the detection of low-volume, but not necessarily more advanced, high-grade tumors in the fi nasteride group. Because a greater proportion of high-grade cancers at prostatectomy were correctly identifi ed by needle biopsy in the fi nasteride group than in the placebo group, it would have been reasonable to expect a higher rate of upgrading from low-to highgrade disease in the placebo group at prostatectomy. However, the low-to-high upgrading rates were similar (25.7% placebo, 23.9% fi nasteride; P = .72), arguing against the detection-bias hypothesis. The up-and downgrading rates are dependent on the prevalence of high-grade disease in the two groups at prostatectomy, which again was higher in the fi nasteride group. Because PSA and DRE are more sensitive for the detection of high-grade prostate cancer in the fi nasteride group than in the placebo group ( 16 , 17 ) , it follows that the fi nasteride group was enriched with more high-grade cancers due to the improved detection properties of these tests. Therefore, treatment comparisons of up-and downgrading may not be as valid as comparisons of biopsy sensitivity to high-grade disease, which does not depend on disease prevalence.
Our study has a number of limitations. First, because long-term outcomes were not followed, prostatectomy results were the only measure of disease outcome available. Second, not all men underwent radical prostatectomy. Differences may exist between the two study groups in the men who did or did not undergo prostatectomy. Third, prostatectomies were sectioned in different manners by different institutions. For those institutions with greater assiduity, there may have been a higher likelihood of better sampling of high-grade disease. This difference also prevented adequate analysis of tumor volumes at prostatectomy. Finally, we assumed that the defi nitions of degenerative changes by the expert panel are hallmarks of a hormonal effect that may have affected grading. Because these changes were also seen in subjects in the placebo group and because it is doubtful that men in the placebo group were taking androgen deprivation therapy without a diagnosis of prostate cancer, it is possible that these degenerative changes were not pathognomonic of a hormonal effect. Thus, it remains possible that histologic changes may develop after fi nasteride administration in some individuals that could affect tumor grading.
It is likely that no single mechanism is suffi cient to explain the increase in high-grade cancer in the fi nasteride group of the PCPT. Although the evidence does not exclude the possibility that fi nasteride may have induced high-grade prostate cancer in some men, the analysis of prostatectomies from the PCPT does indicate that the relative increase in high-grade tumors in the fi nasteride group is less than originally believed. This evidence further suggests that increased detection due to reduced gland volume and selective inhibition of low-grade tumors may have contributed to the fi nasteride-associated increase in high-grade disease. The systematic blinded pathologic examinations in this study of the highgrade biopsies and all available prostatectomy specimens from a large number of men in the PCPT contribute important data to the debate on how to interpret the study's overall results.
